• 1. Emerging investigator series: heterogeneous reactions of sulfur dioxide on mineral dust nanoparticles: from single component to mixed components?
  Tao Wang,Yangyang Liu,Yue Deng,Hongbo Fu,Jianmin Chen Environ. Sci.: Nano, 2018,5, 1821-1833
• 2. Examination of ammonia–poly(pyrrole) interactions by piezoelectric and conductivity measurements
  Analyst, 1991,116, 1125-1130
• 3. Enabling shape memory and healable effects in a conjugated polymer by incorporating siloxane via dynamic imine bond?
  Yaling Zhang,Chunhui Dai,Shiwei Zhou,Bin Liu Chem. Commun., 2018,54, 10092-10095
• 4. Fe(ii)-Assisted one-pot synthesis of ultra-small core–shell Au–Pt nanoparticles as superior catalysts towards the HER and ORR?
  Yi Cao,Yujiao Xiahou,Lixiang Xing,Xiang Zhang,Hong Li,ChenShou Wu,Haibing Xia Nanoscale, 2020,12, 20456-20466
• 5. Dissociation of aryl sulfonyl phthalimide radical anions: relevance to the biological activity of arylsulfonyl amides?
  Abdelaziz Houmam,Emad M. Hamed Chem. Commun., 2012,48, 11328-11330

• Solvents and Organic Chemicals Organic Compounds Organic acids and derivatives Carboxylic acids and derivatives Amino acids, peptides, and analogues Amino acids and derivatives

Benazepril Ethyl Ester (CAS No. 103129-58-4): An Overview of Its Properties and Applications

Benazepril Ethyl Ester (CAS No. 103129-58-4) is a prodrug of benazepril, a well-known angiotensin-converting enzyme (ACE) inhibitor used in the treatment of hypertension and heart failure. This compound has gained significant attention in the pharmaceutical industry due to its unique properties and potential therapeutic benefits. In this comprehensive overview, we will delve into the chemical structure, pharmacological properties, and recent research advancements related to Benazepril Ethyl Ester.

Chemical Structure and Synthesis

Benazepril Ethyl Ester is a derivative of benazepril, with the ethyl ester group attached to the carboxylic acid moiety. The chemical formula of Benazepril Ethyl Ester is C₂₄H₃₀N₂O₅, and its molecular weight is 426.51 g/mol. The synthesis of Benazepril Ethyl Ester typically involves the esterification of benazepril with ethanol in the presence of a suitable catalyst, such as sulfuric acid or p-toluenesulfonic acid. This process yields a stable and bioavailable prodrug that can be further processed for pharmaceutical applications.

Pharmacological Properties

Benazepril Ethyl Ester is designed to enhance the oral bioavailability and stability of benazepril. Upon ingestion, it undergoes hydrolysis in the liver, releasing the active form, benazeprilat. Benazeprilat is a potent ACE inhibitor that effectively blocks the conversion of angiotensin I to angiotensin II, a potent vasoconstrictor. This mechanism leads to vasodilation, reduced blood pressure, and improved cardiac function. The pharmacokinetic profile of Benazepril Ethyl Ester

Clinical Applications and Efficacy

The clinical applications of Benazepril Ethyl Ester are primarily focused on the management of hypertension and heart failure. Numerous clinical trials have demonstrated its efficacy in lowering blood pressure and improving cardiovascular outcomes. For instance, a recent study published in the Journal of Hypertension found that patients treated with benazepril-based medications, including those derived from Benazepril Ethyl Ester, showed significant reductions in systolic and diastolic blood pressure compared to placebo groups. Additionally, these patients experienced fewer cardiovascular events, such as myocardial infarction and stroke.

Safety Profile and Side Effects

The safety profile of Benazepril Ethyl Ester is generally favorable, with common side effects including dizziness, headache, and fatigue. These side effects are typically mild and transient. However, like other ACE inhibitors, it can cause more serious side effects such as hyperkalemia (elevated potassium levels) and renal impairment in certain patient populations. Therefore, regular monitoring of electrolyte levels and kidney function is recommended for patients on long-term therapy.

Latest Research Developments strong > p > < p >Recent research has explored the potential of< strong > Benazepr il Eth yl Est er< /stron g > in novel therapeutic applications beyond hypertension and heart failure. For example, studies have investigated its use in treating diabetic nephropathy due to its renoprotective effects. A study published in the American Journal of Nephrology reported that< strong > Benaz e pr il Et h yl Es ter< /st rong > significantly reduced proteinuria and slowed the progression of kidney disease in diabetic rats. These findings suggest that it may have broader therapeutic utility in managing chronic kidney diseases. p > < p >Another area of interest is the potential role of< strong > Benaz e pr il Et h yl Es ter< /st rong > in neurodegenerative disorders. Preliminary studies have shown that ACE inhibitors may have neuroprotective effects by reducing oxidative stress and inflammation in the brain. While more research is needed to confirm these findings, they open up exciting possibilities for future therapeutic applications. p > < p >< strong >Conclusion< /st rong > p > < p >< strong >Benaz e pr il Et h yl Es ter< /st rong > (CAS No . 103129-58-4) is a promising compound with significant therapeutic potential . Its unique properties , including enhanced oral bioavailability and stability , make it an attractive option for treating hypertension , heart failure , and potentially other conditions such as diabetic nephropathy . Ongoing research continues to uncover new applications , further solidifying its importance in the pharmaceutical industry . As more studies are conducted , we can expect to see even greater advancements in our understanding and utilization of this valuable compound . p > article > response >

• 131064-75-0(ent-Benazepril)
• 182821-27-8(SLV 306)
• 1356010-96-2(Benazepril tert-Butyl Ester-d5)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)